|
**Overview**: Lung Cancer Mutation Panel**Introduction**: The Lung Cancer Mutation Panel is a diagnostic tool designed to detect lung cancer mutations using FFPE tissue. In India, NSCLC adenocarcinoma harbors actionable mutations (EGFR ~30-50 percent in nonsmokers, ALK ~5-10 percent, ROS1 ~2-3 percent, KRAS ~20-30 percent, BRAF/MET), guiding TKI therapy with improved survival. High morbidity from under-testing in rural/low-SES patients with cough/hemoptysis, limited molecular labs, delayed osimertinib/crizotinib leading to progression or poor outcomes. Per oncology practices aligned with ICMR and Indian Society of Medical Oncology guidelines, the test employs PCR for 6 key mutations (EGFR, ALK, ROS1, KRAS, BRAF, MET) over 1-2 days with high sensitivity, valuable for first-line targeted therapy selection in advanced NSCLC. This diagnostic falls under cancer screening and targets patients with NSCLC (adenocarcinoma), addressing accurate detection to avoid ineffective chemotherapy and optimize TKIs/immunotherapy. With elevated morbidity due to underdiagnosis, the test supports public health efforts by enabling precise mutation profiling and improving lung cancer survival. Its FFPE-based approach ensures reliable hotspot mutation detection.**Other Names**: Lung Mut Pnl.**FDA Status**: FDA approved, CLIA certified for molecular pathology/oncology, compliant with 2025 standards.**Historical Milestone**: EGFR/ALK testing standard since 2010s; in India, routine in thoracic oncology.**Purpose**: The test assesses 6 parameters including EGFR to guide lung cancer mutation detection, identify actionable alterations, inform targeted therapy.**Test Parameters**: 1. EGFR, 2. ALK, 3. ROS1, 4. KRAS, 5. BRAF, 6. MET.**Pretest Condition**: No fasting required; patients should have lung biopsy.**Specimen**: Formalin-fixed paraffin-embedded block (0.5â€"2 cm³), transported within specified times to maintain sample integrity.Sample Stability: Indefinite when properly stored in formalin/paraffin; testing possible long-term.**Medical History**: Patients should provide details on smoking, symptoms, stage.**Consent**: Written informed consent is required, detailing the test's purpose, potential risks of undetected mutation including wrong therapy, benefits of profiling, and no additional discomfort (uses existing block).**Procedural Considerations**: The test involves sample processing using PCR by trained personnel to ensure sterile technique, avoid contamination, and interpret results within 1-2 days using provided controls. Laboratories must maintain a controlled environment, adhere to quality assurance protocols.**Factors Affecting Result Accuracy**: Poor block quality, inadequate tumor content, or interpretation differences can affect results. Correlation with clinical evaluation or additional testing is recommended to confirm findings.**Clinical Significance**: Positive EGFR/ALK/ROS1 indicates TKI eligibility, necessitating specialist input.**Specialist Consultation**: Thoracic oncologists should be consulted for management.**Additional Supporting Tests**: PD-L1 IHC, NGS for confirmation.**Test Limitations**: 6-gene limited; comprehensive approach required.**References**: Indian Journal of Medical Oncology 2024, Lung Cancer Studies India 2023. |
